Home/ Stocks/ ASMB

Assembly Biosciences, Inc

ASMB XNAS

$26.68 +0.23 (+0.87%) ▲ 15-min delayed

Open

$27.07

High

$27.12

Low

$26.36

Volume

119.8K

Market Cap

$524.17M

About Assembly Biosciences, Inc

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 73 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$8.21M	$-9,079,000	$-0.54
FY 2025	$72.30M	$-6,122,000	$-0.55
Q3 2025	$10.79M	$-9,196,000	$-0.72
Q2 2025	$9.63M	$-10,198,000	$-1.33

Related Market News

No specific coverage for ASMB yet. Check out our latest market news or earnings calendar.

Get ASMB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Assembly Biosciences, Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.